Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing–remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up
- 1 October 2015
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 287, 64-70
Abstract
No abstract availableKeywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (175031, 175038)
This publication has 39 references indexed in Scilit:
- Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple SclerosisPLOS ONE, 2013
- Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple SclerosisPLOS ONE, 2011
- Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosisBMC Neurology, 2011
- EAE mediated by a non‐IFN‐γ/non‐IL‐17 pathwayEuropean Journal of Immunology, 2010
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Detection of Gene Expression in an Individual Cell Type within a Cell Mixture Using Microarray AnalysisPLOS ONE, 2009
- Compromised CD4+ CD25high regulatory T‐cell function in patients with relapsing‐remitting multiple sclerosis is correlated with a reduced frequency of FOXP3‐positive cells and reduced FOXP3 expression at the single‐cell levelImmunology, 2007
- Multiple sclerosis: a complicated picture of autoimmunityNature Immunology, 2007
- Transcription-Based Prediction of Response to IFNβ Using Supervised Computational MethodsPLOS Biology, 2004
- Rating neurologic impairment in multiple sclerosisNeurology, 1983